Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Zachary Wallace, MD, MSc

Massachusetts General Hospital
Newton, MA, United States

Dr. Wallace is a rheumatologist and clinical epidemiologist at Massachusetts General Hospital and Harvard Medical School. His clinical and research interests are in vasculitis, IgG4-related disease, and COVID-19 in patients with rheumatic disease. He is the Co-Director of Rheumatology and Allergy Clinical Epidemiology Research Center and Co-Director of the Rheumatology Vasculitis Program in the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital. His research has been funded by the NIH, Rheumatology Research Foundation, industry, philanthropy, and Mass General Hospital. He is a member of the Finance Committee of the ACR and a former Chair of RheumPAC.

Presentation(s):

  • 0203: Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): BioCryst: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, April 1, 2023); Horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); MedPace: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Terminated, February 1, 2023); PPD: Consultant (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Shionogi: Advisor or Review Panel Member (Terminated, May 1, 2022); Visterra: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zenas: Advisor or Review Panel Member (Terminated, January 1, 2023), Consultant (Terminated, January 1, 2023)

  • Meet the Panel: COVID-19

    Sunday, November 12, 2023
    11:00 AM – 11:45 AM PT

    Disclosure(s): BioCryst: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, April 1, 2023); Horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); MedPace: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Terminated, February 1, 2023); PPD: Consultant (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Shionogi: Advisor or Review Panel Member (Terminated, May 1, 2022); Visterra: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zenas: Advisor or Review Panel Member (Terminated, January 1, 2023), Consultant (Terminated, January 1, 2023)

  • 0827: Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease

    Sunday, November 12, 2023
    5:00 PM – 5:10 PM PT

    Disclosure(s): BioCryst: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, April 1, 2023); Horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); MedPace: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Terminated, February 1, 2023); PPD: Consultant (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Shionogi: Advisor or Review Panel Member (Terminated, May 1, 2022); Visterra: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zenas: Advisor or Review Panel Member (Terminated, January 1, 2023), Consultant (Terminated, January 1, 2023)

  • 0853: Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System

    Sunday, November 12, 2023
    4:00 PM – 4:10 PM PT

    Disclosure(s): BioCryst: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, April 1, 2023); Horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); MedPace: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Terminated, February 1, 2023); PPD: Consultant (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Shionogi: Advisor or Review Panel Member (Terminated, May 1, 2022); Visterra: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zenas: Advisor or Review Panel Member (Terminated, January 1, 2023), Consultant (Terminated, January 1, 2023)

  • 1542: The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): No relevant disclosure to display

  • 2495: Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

    Tuesday, November 14, 2023
    3:00 PM – 3:10 PM PT

    Disclosure(s): No relevant disclosure to display